These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

283 related items for PubMed ID: 29152124

  • 1. Identification of a sixteen-microRNA signature as prognostic biomarker for stage II and III colon cancer.
    Jacob H, Stanisavljevic L, Storli KE, Hestetun KE, Dahl O, Myklebust MP.
    Oncotarget; 2017 Oct 20; 8(50):87837-87847. PubMed ID: 29152124
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Non-small cell lung cancer associated microRNA expression signature: integrated bioinformatics analysis, validation and clinical significance.
    Li C, Yin Y, Liu X, Xi X, Xue W, Qu Y.
    Oncotarget; 2017 Apr 11; 8(15):24564-24578. PubMed ID: 28445945
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Clinical value of integrated-signature miRNAs in colorectal cancer: miRNA expression profiling analysis and experimental validation.
    Chen X, Shi K, Wang Y, Song M, Zhou W, Tu H, Lin Z.
    Oncotarget; 2015 Nov 10; 6(35):37544-56. PubMed ID: 26462034
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Genome-wide Discovery and Identification of a Novel miRNA Signature for Recurrence Prediction in Stage II and III Colorectal Cancer.
    Kandimalla R, Gao F, Matsuyama T, Ishikawa T, Uetake H, Takahashi N, Yamada Y, Becerra C, Kopetz S, Wang X, Goel A.
    Clin Cancer Res; 2018 Aug 15; 24(16):3867-3877. PubMed ID: 29514841
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Identification and functional characterization of microRNAs reveal a potential role in gastric cancer progression.
    Li CY, Liang GY, Yao WZ, Sui J, Shen X, Zhang YQ, Peng H, Hong WW, Ye YC, Zhang ZY, Zhang WH, Yin LH, Pu YP.
    Clin Transl Oncol; 2017 Feb 15; 19(2):162-172. PubMed ID: 27173517
    [Abstract] [Full Text] [Related]

  • 12. A Novel Necroptosis-Related miRNA Signature for Predicting the Prognosis of Breast Cancer Metastasis.
    Zheng L, Wang J, Jiang H, Dong H.
    Dis Markers; 2022 Feb 15; 2022():3391878. PubMed ID: 35371342
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Profiling of metastatic small intestine neuroendocrine tumors reveals characteristic miRNAs detectable in plasma.
    Bowden M, Zhou CW, Zhang S, Brais L, Rossi A, Naudin L, Thiagalingam A, Sicinska E, Kulke MH.
    Oncotarget; 2017 Aug 15; 8(33):54331-54344. PubMed ID: 28903345
    [Abstract] [Full Text] [Related]

  • 15. Diagnostic microRNA markers to screen for sporadic human colon cancer in stool: I. Proof of principle.
    Ahmed FE, Ahmed NC, Vos PW, Bonnerup C, Atkins JN, Casey M, Nuovo GJ, Naziri W, Wiley JE, Mota H, Allison RR.
    Cancer Genomics Proteomics; 2013 Aug 15; 10(3):93-113. PubMed ID: 23741026
    [Abstract] [Full Text] [Related]

  • 16. A four-microRNA classifier as a novel prognostic marker for tumor recurrence in stage II colon cancer.
    Jacob H, Stanisavljevic L, Storli KE, Hestetun KE, Dahl O, Myklebust MP.
    Sci Rep; 2018 Apr 18; 8(1):6157. PubMed ID: 29670141
    [Abstract] [Full Text] [Related]

  • 17. microRNA Expression Profile in Single Hormone Receptor-Positive Breast Cancers is Mainly Dependent on HER2 Status-A Pilot Study.
    Kunc M, Popęda M, Niemira M, Szałkowska A, Bieńkowski M, Pęksa R, Łacko A, Radecka BS, Braun M, Pikiel J, Litwiniuk M, Pogoda K, Iżycka-Świeszewska E, Krętowski A, Żaczek AJ, Biernat W, Senkus-Konefka E.
    Diagnostics (Basel); 2020 Aug 20; 10(9):. PubMed ID: 32825530
    [Abstract] [Full Text] [Related]

  • 18. Characteristic miRNA expression signature and random forest survival analysis identify potential cancer-driving miRNAs in a broad range of head and neck squamous cell carcinoma subtypes.
    Nunez Lopez YO, Victoria B, Golusinski P, Golusinski W, Masternak MM.
    Rep Pract Oncol Radiother; 2018 Aug 20; 23(1):6-20. PubMed ID: 29187807
    [Abstract] [Full Text] [Related]

  • 19. Novel prognostic and predictive microRNA targets for triple-negative breast cancer.
    Turashvili G, Lightbody ED, Tyryshkin K, SenGupta SK, Elliott BE, Madarnas Y, Ghaffari A, Day A, Nicol CJB.
    FASEB J; 2018 May 29; ():fj201800120R. PubMed ID: 29812973
    [Abstract] [Full Text] [Related]

  • 20. Identification of a circulating microRNA signature to distinguish recurrence in breast cancer patients.
    Huo D, Clayton WM, Yoshimatsu TF, Chen J, Olopade OI.
    Oncotarget; 2016 Aug 23; 7(34):55231-55248. PubMed ID: 27409424
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.